The strategies aimed at reducing UHRF1 activity in retinoblastoma cells enhance sensitivity to HDAC inhibitors, offering another potential therapeutic approach by exploiting the interplay between HDACs and UHRF1 in retinoblastoma progression. This evidence concerns the gene HDAC9 and retinoblastoma.